AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

After hours: March 24 at 4:37:03 PM EDT Loading Chart for XBIT ...

After hours: March 19 at 5:28:49 p.m. EDT Loading Chart for ANAB ...

After hours: 20 March at 18:51:47 GMT-4 Loading Chart for ANAB ...